artificial pancreas

By Dave Muoio 12:26 pm May 20, 2019
On Friday, the FDA issued a warning to patients and providers describing the dangers of diabetes management devices and software that haven’t been assessed by the agency. These include any unapproved or unauthorized continuous glucose monitors, insulin pumps and automated insulin dosing systems, whether used as a standalone device or integrated as part of a glucose management system. “These...
By Dave Muoio 03:32 pm January 28, 2019
A recent paper published in Diabetes Technology & Therapeutics describes the design, safety and basic efficacy of a device-agnostic smartphone app that can interface with continuous glucose monitors, insulin pump devices and dosing algorithms from various manufacturers. Run on an unlocked smartphone, the interoperable Artificial Pancreas System (iAPS) smartphone app was reliable and generally...
By Dave Muoio 11:46 am October 3, 2018
Pediatric and adult Type 1 diabetes patients receiving a hybrid closed-loop artificial pancreas therapy demonstrated improved glucose control and lower risk of hypoglycemia compared to those managing their own glucose levels with an insulin pump and continuous glucose monitor, according to a study published today in the Lancet. The investigation, which was supported by JDRF and presented at the...
By MobiHealthNews 01:55 pm August 13, 2018
Bankrupting docs? Patient booking platform Zocdoc is putting providers in a sticky situation, CNBC reports. The platform, which lets patients book and cancel appointments, is changing its business model. Now instead of charging providers a flat annual rate per doctor, it proposes to charge a lower annual rate as well as a booking fee for each new customer. Not only would this dramatically...
By Dave Muoio 04:17 pm June 25, 2018
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players. The meeting included presentation on studies covering a range of technologies, such as continuous glucose monitors, insulin pumps, apps, and other digital-backed management strategies. Among the studies highlighted by the association was an...
By Laura Lovett 02:03 pm March 20, 2018
In-home hybrid closed-loop system MiniMed from Medtronic can help kids with Type 1 diabetes improve their glycemic outcomes, according to a recent abstract that was presented at the meeting of Endocrine Society in Chicago on Saturday.  "The MiniMed 670G system can effectively manage diabetes and lead to improved time in the target glucose range and glycated hemoglobin (hemoglobin A1c) for...
By Dave Muoio 11:24 am February 5, 2018
The Juvenile Diabetes Research Foundation (JDRF) and Massachusetts-based Cam Med, a company specializing in microfluidic-based drug delivery technologies, announced a partnership today focused on development of a thin, flexible, patch-based insulin pump for artificial pancreas systems. "JDRF is excited to partner with Cam Med on improving insulin delivery hardware,” Jaime Giraldo, program...
By Dave Muoio 01:28 pm December 18, 2017
Milpitas, California-based diabetes management device maker Bigfoot Biomedical has raised $37 million in Series B funding in a round co-led by funds from Janus Henderson Investors and Quadrant Capital Advisors. Additional participants included Cormorant Asset Management, Senvest Capital Inc., Senvest Management LLC, Visionnaire Ventures, JDRF T1D Fund, and T1D Exchange. Bigfoot previously...
By Dave Muoio 04:55 pm December 8, 2017
Heads of the FDA’s Center for Devices and Radiological Health (CDRH) recently penned a blog post describing their previous and ongoing efforts with closed-loop artificial pancreas manufacturers to ensure proper testing and validation of the devices.  In it, Courtney Lias, director of the Division of Chemistry and Toxicology Devices at CDRH, and Stayce Beck, chief of the Diabetes Diagnostics...
By Dave Muoio 04:33 pm December 8, 2017
Indianapolis-based pharmaceutical Eli Lilly and Company announced this week that the first Type 1 diabetes patient has been dosed in a feasibility study of the company’s investigational Automated Insulin Delivery (AID) system. The company’s hybrid closed-loop platform consists of an insulin pump with a dedicated controller for system inputs, a dosing algorithm, and a continuous glucose monitor (...